Table 4. Cox regression model for the association between low-density lipoprotein cholesterol and mortality.

	HR (95% CI) per 1 mmol/l	p
model 1	0.44 (0.26–0.74)	0.002
model 2	0.44 (0.26–0.74)	0.002
model 3	0.44 (0.26–0.74)	0.002
model 4	0.38 (0.22–0.68)	0.0009
model 5	0.18 (0.07–0.47)	0.0005
model 6	0.18 (0.07–0.47)	0.0005

Model 1: unadjusted analysis. Model 2: analysis adjusted for age and sex. Model 3: analysis adjusted for age, sex, diabetes, body mass index (BMI), statin use, hypertension, smoking. Model 4: analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, high density lipoprotein cholesterol (HDL-C), triglycerides. Significant predictor of death were: low-density lipoprotein cholesterol (LDL-C) and HDL-C (0.24; 0.08–0.66). Model 5: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, HDL-C, triglycerides, World Health Organization functional class (WHO-FC), etiology of pulmonary arterial hypertension (PAH), PAH-specific treatment at the end of observation, N-terminal pro-brain natriuretic peptide (NT-proBNP), 6-minute walk distance (6-MWD), right atrial pressure (RAP), pulmonary vascular resistance, cardiac index (CI). Significant predictors of death were: LDL-C and current smoking (6.8; 1.3–35.6), NT-proBNP (1.02; 1.01–1.03), RAP (1.12; 1.02–1.25). Model 6: Analysis adjusted for age, sex, diabetes, BMI, statin use, hypertension, smoking, HDL-C, triglycerides, WHO-FC, etiology of PAH, PAH-specific treatment at the end of observation, NT-proBNP, 6-MWD, RAP, mean pulmonary artery pressure, CI. Significant predictors of death were: LDL-C and current smoking (6.8; 1.3–35.6), NT-proBNP (1.02; 1.01–1.03), RAP (1.12; 1.02–1.25).